SciClone Pharmaceuticals Overview

SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. Our strategy is to in-license late-stage clinical products and develop them for commercialization in the United States, Europe, and China, one of the world’s fastest growing pharmaceutical markets.

Our lead product ZADAXIN®, our...More»

SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. Our strategy is to in-license late-stage clinical products and develop them for commercialization in the United States, Europe, and China, one of the world’s fastest growing pharmaceutical markets.

Our lead product ZADAXIN®, our brand of thymalfasin, is one of the largest selling imported drugs in China today based on revenues, and ZADAXIN also is approved in several other promising international markets. For the U.S. and Europe, we are evaluating thymalfasin in a nearly completed phase 3 trial for the hepatitis C virus (HCV) and a planned phase 3 trial for malignant melanoma. For the U.S., we are conducting a phase 2 HCV trial for SCV-07 and a phase 2 pancreatic cancer trial for RP101.

(Source: SciClone Pharmaceuticals)«Less